CXI Healthcare Technology Group Limited Overview
CXI Healthcare Technology Group is a Cayman-incorporated holding company listed on KOSDAQ. Its operating businesses are in Fujian Province, China. It manufactures health supplements based on traditional Chinese medicine (TCM), sold as capsules, tablets, granules, drinks and teas, and distributes raw materials such as cordyceps, tea leaves and herbal inputs [S1][S37]. Since 2019 it has added a small cosmetics-distribution business, which brings Korean and Japanese skincare brands into China [S8][S15]. Earlier in its listed life the company reported revenue in the hundreds of billions of KRW. In FY2025 revenue fell to KRW 57.6 bn [S2], and recent quarters show gross losses [S27]. The balance sheet is large and almost debt-free (equity KRW 491.6 bn at June 2025) [S2], yet the market capitalisation is a small fraction of book value. In 2026 the company recapitalised under its CEO to stay listed under tighter KOSDAQ rules. In October 2026 it agreed to buy 55% of a Chinese enterprise-AI data company, which redirects the group toward AI services [S3][S5].
What the company does
Self-description. In its filings and profiles, the group says it makes and sells health foods in China through subsidiaries. The products are TCM-based supplements in capsule, tablet, drink and tea formats [S1][S30]. A Korean-language profile derived from the company's disclosures adds three points [S37]:
-
the group runs a raw-material distribution business covering cordyceps and tea leaves;
-
the cosmetics unit sells TUNEMAKERS skincare through JD.com, Tmall Global and other major online platforms.
Morningstar's profile states that all products are marketed only in China [S30].
Independent characterisation. CXI is a small, mostly domestic Chinese consumer-health company. Its listed shell has been used repeatedly for capital-structure transactions, and it is now being repositioned. Three features stand out:
-
Operating shrinkage. Revenue moved from the mid-2010s scale cited in Korean press to KRW 57.6 bn in FY2025 [S2]. It then fell to a run-rate below KRW 8 bn per quarter by the March 2026 quarter [S27].
-
Asset-heavy, cash-and-plantation balance sheet. Total assets were KRW 575.2 bn at March 2026 [S26], against trailing revenue of KRW 51.4 bn [S25]. Depreciation and amortisation embedded in cost of sales was about KRW 24–26 bn per year [S25], which points to large plantation or land-use assets.
-
Strategic pivot to AI. The October 2026 decision to buy 55% of AIDT Technologies Limited [S3] would make AI data services the largest revenue line on consolidation. AIDT's H1 2026 revenue (USD 36.97 m, about KRW 53.6 bn) is larger than CXI's trailing twelve-month revenue [S3][S25].
Business model and revenue model
| Revenue type | Description | Approximate weight |
|---|---|---|
| Product sales: health supplements | Own-manufactured TCM-based supplements (capsules, tablets, granules, drinks), sold to distributors and retailers | Not publicly disclosed (FY2025) |
| Product sales: general foods / tea | Traditional teas, including Pu'er from an acquired plantation | — |
| Distribution: raw materials | Trading of cordyceps, herbal inputs and tea leaves, at lower margin | — |
| Distribution: cosmetics | Exclusive or general distribution of third-party brands (TUNEMAKERS, Answer Garden) and co-developed products | Not publicly disclosed; small |
| Prospective: AI services (AIDT) | AI data collection and processing, data governance, model training and fine-tuning, industry AI applications | Not yet consolidated as of the decision date |
There is no subscription or licensing revenue. The model is product and trading revenue. In 2012 management gave segment gross-margin guides of about 70% for health foods, 20–30% for distribution and about 50% for tea [S22]. Current segment margins are not disclosed.
Value-chain position
The group is vertically integrated from cultivation to branded product. It acquired a large Chinese-herbal plantation in 2015 [S16] and a Pu'er tea plantation in 2020 [S10]. It runs a tea-cultivation complex and a research lab [S8], manufactures in Fujian [S18], and sells through distributors and retail. In cosmetics it acts as a brand distributor or incubator, not a manufacturer [S7][S15].
Customers and end-markets
Channels (health foods): Hypermarkets, supermarkets, pharmacies, health-food specialty stores and tea houses, mostly through wholesale or general distributors (총판) [S18].
Channels (cosmetics): JD.com, Taobao, Tmall Global and Xiaohongshu online. Offline, the business supplies franchise cosmetics retailers and agents. A Watsons China supply agreement was signed in October 2020 [S17].
End-markets: Chinese consumer health and wellness, Chinese tea, Chinese skincare and, prospectively, Chinese enterprise AI.
Strategy
Stated strategy (paraphrased from company statements)
In February 2026 the company described a programme to keep its listing, protect shareholder value and restore the share price. It rested on four pillars [S6]:
-
profitability-focused management;
-
stronger competitiveness of the core business;
-
securing new growth engines;
-
better financial soundness and management efficiency.
Management added that it would consider any other reasonable measure to meet listing requirements and leave "low-priced stock" status [S6].
In March 2026 the company presented the capital reduction as groundwork for future shareholder-return policies, including possible dividends, and not as a response to financial distress [S2].
Initiatives in the last 24 months (Oct 2024 – Oct 2026)
| Date | Initiative | Type | Detail | Source |
|---|---|---|---|---|
| Oct 2024 | Beautyskin placement and MOU | Partnership / cosmetics | KRW 1.0 bn equity from Beautyskin; joint R&D on tea-leaf extracts; cross-distribution | [S8] |
| Jul–Aug 2025 | 10:1 share consolidation | Capital structure | Shares to 30,054,138 | [S11] |
| Oct 2025 | K-indie brand strategy; Answer Garden distribution | New business line | Dedicated task force for brand incubation and sourcing; more brands targeted within the year | [S7] |
| Feb 2026 | Listing-maintenance and value-up programme | Governance / strategy | Four pillars (above) | [S6] |
| Mar 2026 | CEO premium placement with 3-year lock-up | Capital / governance | KRW 730 per share, 67.7% premium | [S4] |
| Mar–Jun 2026 | 80% par reduction and 5:1 consolidation | Capital structure | Pre-empts the 1 Jul 2026 KOSDAQ rules (KRW 20 bn market-cap floor; delisting route for sub-KRW 1,000 stocks) | [S2] |
| Jun 2026 | Second CEO placement | Capital | CEO's March and June investments total about KRW 10.7 bn | [S5] |
| Jul–Aug 2026 | KRW 48 bn third-party placement | Capital | CEO KRW 19.2 bn for 3.2 m shares | [S5][S12] |
| Jul 2026 | CEO on-market purchase plan | Governance signal | 700,000 shares (4.2% of shares as then stated), 8 Oct – 6 Nov 2026, about KRW 760 m | [S5] |
| Oct 2026 | AIDT Technologies 55% acquisition | Transformational M&A | USD 45.37 m; enterprise AI data and software | [S3] |
Medium-term targets / guidance
No quantitative revenue, margin or return targets were disclosed in the sources reviewed. The only forward-looking figures relate to AIDT and come from an external valuation firm: consolidated AIDT revenue of about USD 52.07 m in 2027 and about 40% compound annual growth through 2029 [S3].
ESG / sustainability commitments
None disclosed. The Answer Garden brand that CXI distributes promotes natural ingredients and recyclable packaging [S7], but that is a brand attribute, not a group commitment.
Products & Services
Health Supplements (own manufacture)
| Product / line | Description and claimed function | Target customer | Launch / latest year | Pricing | Source |
|---|---|---|---|---|---|
| 영생활력 ("Yongsheng Huoli") brand, incl. anti-aging/fatigue line | Flagship TCM-herbal supplement brand in capsule, tablet, granule and tea formats; positioned for fatigue improvement and anti-aging | Adult Chinese consumers | Main brand cited 2020–2025 | — | [S10][S13][S37] |
| Cordyceps-based supplements | Products using cultured cordyceps; the company claims small amounts of cordyceps achieve efficacy through its cultivation method. Cordyceps was the largest sales item as of 2022 | Adult/middle-aged consumers | Since founding | — | [S21][S13] |
| 금려강 Capsules (Jinlijiang) | Menopausal-symptom relief; 12% of FY2009 sales | Women in menopause | Pre-IPO | — | [S20] |
| 건력강 Tablets (Jianlijiang) | Male sexual-function support; 12% of FY2009 sales | Adult men | Pre-IPO | — | [S20] |
| 삼청보 Tablets (Sanqingbao) | Constipation relief; 9% of FY2009 sales | General adult | Pre-IPO | — | [S20] |
| 건뇌영 Capsules (Jiannaoning) | Fatigue recovery; 6% of FY2009 sales | General adult | Pre-IPO | — | [S20] |
| 12-product new supplement pipeline | Immunity, digestion, diabetes adjunct and memory improvement; awaited CFDA administrative approval in Oct 2016. | Adults | 2016–2017 (expected) | — | [S16][S23] |
| Cistanche (종용) products | Domestic Chinese health products based on cistanche | Adults | Cited 2022 | — | [S13] |
General Foods / Tea
| Product / line | Description | Source |
|---|---|---|
| Traditional teas | Premium and traditional tea; the general-foods division recovered in FY2021 | [S10][S18] |
| Pu'er tea | From the plantation acquired in 2020; described by the company as high-margin | [S10][S13] |
Raw Material Distribution
| Product | Description | Source |
|---|---|---|
| Cordyceps (동충하초) | Distribution of cordyceps raw material | [S18][S37] |
| TCM herbal inputs | From the herbal cultivation complex acquired in 2015; primary processing | [S16] |
| Tea leaves | Distribution from cultivation assets | [S37] |
Cosmetics (distribution and co-development)
| Brand / product | Owner / partner | Scope | Year | Source |
|---|---|---|---|---|
| Mask packs (own or co-developed) | Korean partners (Humedix MOU) | Watsons China online and offline; JD.com, Taobao, Tmall Global, Xiaohongshu. Jun–Sep 2020 sales of about RMB 1.03 m. Ampoule and sunscreen line extensions planned | 2,020 | [S9][S17] |
| TUNEMAKERS | RAFRA (Japan; acquired by Unilever in Oct 2019) | Distribution in China. The brand's prior-year China sales were cited at about RMB 200 m | 2,022 | [S15] |
| Answer Garden | Kovix (Korean manufacturer) | Exclusive China distribution of 15 SKUs: ampoule, toner, foam cleanser, moisturising cream, mist and mask pack. A dedicated task force will incubate further K-indie brands | 2,025 | [S7] |
| Beautyskin co-development | Beautyskin (Korea-listed) | Joint R&D on tea-leaf-extract cosmetic ingredients using CXI's tea complex and lab; cross-distribution | 2,024 | [S8] |
Prospective: AI Services (AIDT Technologies)
| Offering | Description | Source |
|---|---|---|
| AI data collection and processing | Core business | [S3] |
| Data governance | Extended service line | [S3] |
| AI model training and fine-tuning | Extended service line | [S3] |
| Industry-specific AI applications | Enterprise AI software | [S3] |
Financial Narrative
Income statement
Sources and derivations:
-
FY2024 revenue, operating income and net income come from a DART-derived summary [S11].
-
FY2025 revenue and net income come from the company statement [S2].
-
FY2025 cost of revenue (KRW 40.32 bn) comes from Valueline [S25]. FY2025 gross profit is derived (57.63 − 40.32). FY2025 revenue in [S25] (57.63) matches [S2] (57.6).
-
Margins and growth are derived.
FY2026: (year to June 2026): the annual report was due by about end-September 2026, but its figures were not located. Nine-month data are in 6.2.
- EBITDA, pre-tax income, EPS (basic/diluted) and DPS: not publicly disclosed in sources reviewed. Google Finance shows an EPS of KRW 1,662 [S27], but its share basis and period are unclear and inconsistent with the net income and share counts above, so it is not relied upon. No dividends were paid [S28].
Quarterly trend — FY2025 Q4 to FY2026 Q3
Sources: Google Finance quarterly data [S27]. Operating income for Q1–Q3 FY26 is derived as revenue minus total operating expenses. Net income for Q2 and Q3 FY26 is from TradingView [S28], which reports the last two quarters as −1.50 bn and −2.45 bn.
Cross-check. The four quarters sum to KRW 51.44 bn. This matches Valueline's trailing-twelve-month (TTM) revenue to March 2026 of KRW 51.44 bn [S25], so the quarterly series is internally consistent.
Nine-month comparison (derived). Revenue for 9M FY2026 was KRW 32.14 bn, against KRW 38.33 bn for 9M FY2025 (57.63 − 19.30). That is a decline of about 16%.
Trailing-twelve-month trend
Source: Valueline annualised series [S25]. Column mapping was verified against the FY2025 company figures [S2] and the Simply Wall St TTM to December 2025 (revenue KRW 54.2 bn, cost of revenue 38.6 bn, gross profit 15.5 bn, earnings 9.9 bn) [S1].
Key observation. Depreciation and amortisation inside cost of revenue rose from about 57% to about 70% of cost of revenue over the period. As a share of revenue it reached about 50% in TTM March 2026 (derived). Raw-material cost fell by roughly a third. The cost base is therefore dominated by fixed asset charges, most plausibly plantation, biological or land-use assets, rather than by variable inputs. This explains why falling sales turned into quarterly gross losses.
Balance sheet
Interim position at 31 March 2026 (Valueline):
-
total assets KRW 575.24 bn;
-
current assets KRW 55.17 bn;
-
cash KRW 47.08 bn;
-
derived non-current assets KRW 520.07 bn [S26].
Sources: Valueline balance sheet [S26]. Liabilities and equity for FY2024 come from [S11] and for FY2025 from [S2]. The FY2025 total assets of 494.2 match across [S2] and [S26]. Goodwill and intangibles, the short/long-term debt split and working-capital detail were not publicly disclosed in sources reviewed. Total liabilities of KRW 2.5 bn at June 2025 [S2] imply no material interest-bearing borrowings.
Red flag requiring scrutiny. Between June 2025 and March 2026:
-
cash fell by about KRW 153 bn (200.5 to 47.1);
-
non-current assets rose by about KRW 245 bn (275.2 to 520.1);
-
total assets rose by about KRW 81 bn (494.2 to 575.2).
Over the same period the group reported net losses in two of three quarters [S28]. Its only disclosed equity inflow before April 2026 was the March 2026 CEO placement (about 7.3 m pre-consolidation shares at KRW 730, roughly KRW 5.3 bn; derived from [S4][S11]). Liabilities had been about KRW 2.5 bn [S2]. Possible explanations include:
-
reclassification of cash into long-term deposits, loans or investments;
-
prepayments for acquisitions;
-
foreign-currency translation effects.
None of these could be verified. The movement should be reconciled against the FY2026 audited statements before any reliance is placed on book value. Note also that the company said in 2022 that IPO proceeds had been moved to the PRC operating entity as intra-group operating loans [S13].
Data conflicts and period attribution
-
FY2024 vs FY2023 labelling. The Digital Today AI disclosure summary (August 2025) labels revenue of KRW 70.4 bn, operating profit of KRW 19.1 bn, net income of KRW 29.7 bn, assets of KRW 483.9 bn, liabilities of KRW 2.7 bn and equity of KRW 481.1 bn as "June 2023" [S11]. Valueline's June 2024 column shows total assets of KRW 483.86 bn, while its June 2023 column shows KRW 415.97 bn [S26]. In August 2025 the latest audited year was FY2024. Users should confirm against DART.
-
Historic scale. Hankyung (April 2015) cites prior-year revenue of KRW 153.5 bn and operating profit of KRW 49.4 bn. The same article quotes a broker forecast of KRW 324.4 bn revenue and KRW 106.3 bn operating profit as +13.3% and +15.9% growth, which implies a base of about KRW 286 bn and 92 bn [S23]. A 2016 interview cites the prior year at KRW 297.6 bn revenue and KRW 70.5 bn operating profit [S16]. A 2014 broker note forecast FY2014 operating profit of KRW 102.9 bn [S24]. These figures cannot all be correct. Either the definitions or the periods differ (possibly half-year vs full-year, or currency-translation bases). They establish only that the business was several times larger in the mid-2010s than in FY2025.
-
P/E and P/B on aggregator sites. StockHub shows P/E 0.73–0.80 and P/B 0.01 [S29]. These appear to use stale share counts.
Cash flow
Cash-flow statements were not publicly disclosed in sources reviewed. TradingView states that the company does not pay dividends [S28]. No company share buyback programme was identified. The CEO's personal on-market purchase plan is not a company buyback.
Ratios (derived)
Derivations:
-
FY2025 ROE uses average equity (481.1 + 491.6)/2. StockHub's 2.53% ROE [S29] is consistent.
-
ROA uses average assets.
-
Asset turnover is revenue divided by average total assets.
-
Not computable: ROIC, current ratio, interest coverage, net debt/EBITDA and the cash conversion cycle, because current liabilities, interest and working-capital detail were not disclosed. With total liabilities of only KRW 2.5 bn against current assets of KRW 219.0 bn at June 2025, the current ratio was at least 87x (derived lower bound). Interest coverage is effectively not meaningful because there is no disclosed debt.
-
5-year revenue CAGR: not computable from verified data.
Commentary: trends, inflections, drivers
Revenue. Revenue has fallen from a mid-2010s base reported in the hundreds of billions of KRW [S16][S23] to KRW 70.4 bn in FY2024, KRW 57.6 bn in FY2025 and KRW 51.4 bn TTM to March 2026 [S11][S2][S25]. The break came in the December 2025 quarter, when revenue more than halved from 16.75 bn to 7.87 bn [S27]. The company has not given a public explanation for that drop in the sources reviewed. The Chinese supplement industry was weak at the same time. By-health, the category leader, reported falling pharmacy footfall and offline supplement sales [S32]. That industry weakness is relevant context, not a confirmed cause.
Margins. Reported profitability was high: a 27.1% operating margin and 42.2% net margin in FY2024, with net income above operating income, which implies large non-operating income such as interest on cash [S11]. FY2025 was weaker at a 22.1% net margin and roughly 30% gross margin [S2][S25]. With depreciation of about KRW 6 bn per quarter fixed in cost of sales, the falling revenue produced gross losses in the last two reported quarters [S27].
Balance sheet. For years the market valued the company at a small fraction of book value, which management itself cited as a long-running undervaluation [S2].
Inflection. If the AIDT acquisition closes, it would roughly double consolidated revenue. AIDT's H1 2026 revenue was USD 36.97 m, about KRW 53.6 bn [S3]. It would also replace the declining health-food P&L as the main earnings driver, with 45% of AIDT's earnings attributable to non-controlling interests.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Jurisdiction | Role | Ownership |
|---|---|---|---|
CXI Healthcare Technology Group Limited | Cayman Islands | Listed holding company | — |
Fujian Jinshan Dadao Biotech Co., Ltd. (복건금산대도생물과기) | PRC (Fujian) | Principal operating subsidiary | 100% (at IPO) |
Fuzhou Jinda Bioengineering Technology Development Co. (복주금대생물공정과기개발) | PRC (Fujian) | Operating sub-subsidiary | 100% indirect (at IPO) |
Jinshan Resources Investment Co., Ltd. (금산자원투자) | Not stated | Group entity shown in 2019 IR structure | — |
CKH Health Industry Co., Ltd. (씨케이에이치건강산업) | Republic of Korea | Cosmetics sourcing and distribution | 100% |
Jieya Star (JIEYA STAR) | Not stated (PRC operating sub) | Cosmetics/consumer distributor | — |
AIDT Technologies Limited | Not stated | Enterprise AI data and software | — |
“—” = not publicly disclosed.
Revenue by Segment
| Segment | FY2024 | FY2025 |
|---|---|---|
Total revenue (KRW Bn) | 70.4 | 57.6 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Margin Analysis (%)
| Metric | FY2024 | FY2025 |
|---|---|---|
Revenue (KRW Bn) | 70.4 | 57.6 |
Cost of revenue (KRW Bn) | — | 40.3 |
Gross profit (KRW Bn) | — | 17.3 |
Operating income (KRW Bn) | 19.1 | — |
Net income (KRW Bn) | 29.7 | 12.7 |
Gross margin (%) | — | 30.0 |
Operating margin (%) | 27.1 | — |
Net margin (%) | 42.2 | 22.1 |
Revenue growth YoY (%) | — | -18.2 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement
| Metric | Q4 FY25 (Apr–Jun 2025) | Q1 FY26 (Jul–Sep 2025) | Q2 FY26 (Oct–Dec 2025) | Q3 FY26 (Jan–Mar 2026) |
|---|---|---|---|---|
Revenue (KRW Bn) | 19.30 | 16.75 | 7.87 | 7.52 |
Cost of goods sold (KRW Bn) | 9.30 | 10.07 | 9.56 | 8.20 |
Gross profit (KRW Bn) | 10.00 | 6.68 | -1.69 | -0.68 |
SG&A (KRW Bn) | 2.09 | 1.79 | 2.28 | 1.80 |
Total operating expenses incl. COGS (KRW Bn) | 11.73 | 11.80 | 11.54 | 10.02 |
Operating income (KRW Bn) | 7.57 | 4.95 | -3.67 | -2.50 |
Net income (KRW Bn) | — | — | -2.45 | -1.50 |
Income Statement (Annual)
| Metric | TTM Mar-2025 | FY Jun-2025 | TTM Sep-2025 | TTM Dec-2025 | TTM Mar-2026 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 64.39 | 57.63 | 55.73 | 54.15 | 51.44 |
Cost of revenue (KRW Bn) | 39.66 | 40.32 | 39.18 | 38.61 | 37.13 |
of which raw materials (KRW Bn) | 16.99 | 16.19 | 14.97 | 13.62 | 11.20 |
of which depreciation & amortisation (KRW Bn) | 22.73 | 24.01 | 24.10 | 24.99 | 25.82 |
Net income (KRW Bn) | 23.61 | 12.74 | 11.22 | 9.92 | 8.65 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Total assets (KRW Bn) | 427.86 | 415.97 | 483.86 | 494.17 |
Current assets (KRW Bn) | 99.85 | 121.30 | 187.11 | 218.98 |
Cash & equivalents (KRW Bn) | 65.71 | 94.62 | 159.91 | 200.53 |
Total liabilities (KRW Bn) | — | — | 2.7 | 2.5 |
Total equity (KRW Bn) | — | — | 481.1 | 491.6 |
Non-current assets (KRW Bn, derived) | 328.01 | 294.67 | 296.75 | 275.19 |
Financial Analysis
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Dividends paid (KRW Bn) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
ROE (%) | — | — | 6.2 | 2.6 |
ROA (%) | — | — | 6.6 | 2.6 |
Liabilities / equity (%) | — | — | 0.56 | 0.51 |
Cash / total assets (%) | 15.4 | 22.7 | 33.0 | 40.6 |
Asset turnover (x) | — | — | 0.15 | 0.12 |
Revenue by Region
| Region | FY2024 | FY2025 |
|---|---|---|
China (KRW Bn) | 70.4 | 57.6 |
Capital Markets
| Item | Value | Date |
|---|---|---|
Last verified close | KRW 4,595 (+29.99%) | 14 Oct 2026 |
Market cap | about KRW 52.1 bn | 14 Oct 2026 |
52-week range (as shown) | KRW 324 – 5,430 | Oct 2026 |
Prior snapshots | KRW 1,053 (26 Jun 2026); KRW 1,091 (16 Jul 2026); KRW 1,168 (24 Jul 2026); KRW 851 (3 Aug 2026), all before the 27 Aug consolidation | 2026 |
All-time high / low (pre-consolidation basis) | KRW 5,524 (30 Apr 2015) / KRW 49 (7 Apr 2025) | — |
1-year performance | −38.61% (TradingView snapshot, mid-2025, pre-consolidation) | 2025 |
3- and 5-year performance | Not reliably computable. | — |
Shares in Issue by Date
| Date | Shares in issue | Basis |
|---|---|---|
Mar 2010 | 80,000,000 | IPO |
Dec 2017 | 110,404,457 | Reported |
Jul 2022 (pre-Jieya) | about 136.8 m | Derived from Wang Yueren's 30,207,162 shares = 22.08% |
Jul 2022 (post-Jieya) | about 174.7 m | Derived: +37,888,166 |
Aug 2025 (post 10:1) | 30,054,138 | Reported |
Mar 2026 (post CEO placement) | 37,348,303 | Reported |
Mid-2026 (post 5:1) | about 7,469,660 | Reported as planned |
Jul 2026 (post June placement) | about 16.7 m | Derived: 700,000 shares = 4.2%; CEO 4,655,309 shares = 27.93% |
31 Aug 2026 (post 27 Aug consolidation and KRW 48 bn placement) | about 11.2–11.3 m | Derived: CEO 4,131,061 = 36.89%; market cap ÷ price |
Valuation Multiples
| Multiple | CXI | Basis |
|---|---|---|
P/E (TTM) | about 6.0x | KRW 52.1 bn ÷ TTM Mar-2026 NI of KRW 8.65 bn [S25][S29] |
P/B | about 0.1x | KRW 52.1 bn ÷ June 2025 equity of KRW 491.6 bn, before the 2026 capital raises [S2] |
EV/Sales (TTM) | about 0.1x | (KRW 52.1 bn − KRW 47.1 bn March-2026 cash) ÷ KRW 51.4 bn. Excludes the August KRW 48 bn raise and the pending AIDT outflow |
EV/EBITDA | Not computable | Operating income is negative TTM; quarterly D&A detail is partial |
Capital Markets — Analyst consensus
| Item | Status |
|---|---|
Analyst consensus | No active coverage identified ("reports 0") |
Historical coverage | Hana Daetoo Buy, TP KRW 6,400 (May 2014) |
Dividend history | No dividends paid |
Dividend policy | Management cites the capital reduction as groundwork for future returns; no policy adopted |
Buyback authorisation | None. CEO personal purchase plan only |
Credit ratings (Moody's, S&P, Fitch) | Not rated |
Debt maturity profile | No disclosed borrowings (total liabilities KRW 2.5 bn, June 2025) |
Analyst Conclusions
Management guidance
No quantitative guidance has been disclosed. The qualitative priorities are profitability, core-business competitiveness, new growth engines and financial efficiency [S6], plus the AIDT consolidation [S3]. The only forward numbers are a third-party projection for AIDT (2027 revenue of about USD 52.07 m; about 40% CAGR to 2029) [S3]. That projection is inconsistent with AIDT's H1 2026 run-rate.
Consensus
None available [S29].
Bull case (grounded in data)
-
Earnings reset from AIDT. AIDT's H1 2026 operating profit of USD 7.24 m (about KRW 10.5 bn) at a 19.6% margin [S3] compares with CXI's TTM net income of KRW 8.65 bn [S25]. Even after the 45% minority share, attributable AI profit could exceed the legacy business's recent earnings.
-
Deep discount to book. A market cap of about KRW 52 bn against KRW 491.6 bn of June 2025 equity [S2][S29] leaves large upside if asset quality is confirmed and cash can be distributed.
-
Aligned controller. The CEO holds 36.89%, has bought shares at premiums (67.7% in March), and has locked them up for 3 years voluntarily [S4][S12].
Bear case (grounded in data)
-
Core business in freefall. Quarterly revenue is down about 61% from June 2025 to March 2026, with gross losses [S27]. A heavy D&A load (about 50% of revenue) means losses persist without a volume recovery [S25].
-
Balance-sheet opacity. About KRW 153 bn of cash left the balance sheet in nine months while non-current assets rose about KRW 245 bn [S26], with no reconciliation available. Book value may not be realisable for minority holders, especially given PRC fund-transfer constraints [S13].
-
Serial dilution and listing risk. Two consolidations in 12 months, a par reduction, and placements totalling at least about KRW 60 bn in 2026 [S2][S4][S5][S12]. KOSDAQ thresholds remain binding if the price falls back.
Catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Why it matters |
|---|---|
| Publication and audit opinion of the FY2026 annual report | Confirms FY2026 losses, reconciles the cash movement, reveals the auditor's opinion |
| AIDT closing, accounting treatment and first consolidated quarter | Tests the revenue and margin claims |
| Use of the KRW 48 bn placement proceeds | Whether it funds AIDT or other uses |
| CEO purchase execution (8 Oct – 6 Nov 2026) | Signal of alignment |
| Market cap staying above KRW 20 bn and price above KRW 1,000 | KOSDAQ listing maintenance |
| Q1 FY2027 (Jul–Sep 2026) legacy revenue | Whether the health-food decline has bottomed |
| Any dividend or return policy | Management has linked the capital reduction to future returns |
| Disclosure of AIDT's customers, data-compliance status and management | Assesses quality of earnings |
Analyst verdict
CXI Healthcare Technology Group is no longer an investment in Chinese health supplements. It is now a special situation, and three facts define it.
First, the legacy business is deteriorating fast. Revenue in the March 2026 quarter was KRW 7.5 bn, against KRW 19.3 bn nine months earlier. The cost base is dominated by depreciation of plantation-type assets, so the business is posting gross losses [S25][S27]. There is no disclosed plan to reverse this beyond a small cosmetics-distribution push [S7].
Second, the balance sheet is both the bull case and the main concern. Reported equity of nearly KRW 500 bn with almost no liabilities [S2] sits next to a market cap of about KRW 52 bn [S29]. That gap has persisted for years, which suggests investors doubt the assets can be realised for minority holders. The KRW 153 bn fall in cash in the nine months to March 2026, matched by a rise in non-current assets [S26], sharpens that doubt until audited statements explain it.
Third, control and direction are now clearly with CEO Lin Jinsheng. He has put in roughly KRW 30 bn in 2026 at premium prices [S4][S5]. He is redirecting the company into enterprise AI through the 55% AIDT purchase, a business that on its own H1 2026 figures is larger and faster-growing than CXI [S3].
The investment case therefore rests on two verifiable questions:
-
Do the FY2026 audited accounts clarify where the cash went, with a clean audit opinion?
-
Do AIDT's revenue and profit translate into consolidated, cash-backed results, given the internal inconsistency between its run-rate and the valuer's 2027 projection?
Until both are answered, the stock should be treated as a high-risk, event-driven position, not a value investment. On the evidence currently available, governance and disclosure risk outweighs the apparent discount to book.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles / background |
|---|---|---|---|
Lin Jinsheng (林金生 / 린진성; also listed as Jin Sheng Lin or Jin Lin) | CEO (대표이사); largest shareholder since Mar 2026 | CEO since at least Oct 2012 | Led the company through the China King Highway and CKH eras |
Wang Yueren (王岳仁 per romanization) | Chairman (2010); "President" (2022); largest shareholder at 22.08% before Jul 2022 | — | Founder-era chairman; Canadian national |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
Feb 2026 | CEO announces intention to raise stake (to 16.96% post-subscription, as planned then) | Listing-maintenance programme |
13 Mar 2026 | CEO becomes largest shareholder with 4,776,547 shares (12.8%) | Premium third-party placement at KRW 730 with a 3-year lock-up |
21 Jul 2026 | CEO stake to rise from 27.93% to 36.45% through a KRW 19.2 bn subscription | KRW 48 bn placement |
31 Aug 2026 | CEO reports 4,131,061 shares (36.89%) | After consolidation (27 Aug) and placement (31 Aug) |
Major Shareholders
| Holder | Stake | Date | Status |
|---|---|---|---|
Lin Jinsheng (CEO) | 36.89% (4,131,061 shares) | 31 Aug 2026 | Latest |
Chen Aizhu (천아이주) | 7.03% (2,112,519 shares after 10:1 consolidation) | 11 Aug 2025 | — |
Ruixing International Holdings Ltd (Hong Kong) | 16.24% | Jul 2022 | — |
Wang Yueren | 22.08% (30,207,162 shares, before the Jieya issue) | Jul 2022 | — |
Other subscribers to the Jul 2026 KRW 48 bn placement (KRW 28.8 bn not taken by the CEO) | — | Aug 2026 | — |
“—” = not publicly disclosed.
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Listing | Relevance | Latest revenue (verified) |
|---|---|---|---|---|
Health supplements (VDS) | By-health (汤臣倍健) | SZSE 300146 | China VDS leader with 9.3% share (2024) | RMB 6,265.5 m (FY2025) |
TCM fungal/cordyceps-derived products | Zhejiang Zuoli Pharmaceutical (佐力药业) | SZSE 300181 | Medicinal-fungus leader (Wuling and Bailing series); owns a Qinghai cordyceps unit | RMB 3,041 m (FY2025) |
TCM health products | Beijing Tong Ren Tang | SSE | Heritage TCM brand | — |
Health supplements (direct selling) | Infinitus (Lee Kum Kee Health) | Private | Major TCM-health direct seller | — |
Health supplements (direct selling) | Amway China; Perfect (China) | Private / subsidiaries | Large supplement direct sellers | — |
Cordyceps-fermentation pharma | Jiangxi Jemincare (Jinshuibao capsule) | Private | Cordyceps-derived OTC | — |
Tea | Large Pu'er and tea brand owners (e.g., Menghai Tea / Dayi) | Private | Pu'er competition | — |
Cosmetics distribution | Brand-partner e-commerce operators (e.g., Baozun) | NASDAQ/HKEX | Foreign-brand distribution in China | — |
AI training data (post-AIDT) | Beijing Haitian Ruisheng (海天瑞声) | SSE STAR 688787 | A-share AI training-data specialist | RMB 377.0 m (FY2025) |
AI training data (post-AIDT) | Appen; Datatang; Innodata | ASX; private; NASDAQ | Global and Chinese data-service peers | — |
Peer Comparison FY2024
| Metric | CXI (FY Jun-2025) | By-health (FY Dec-2025) | Zuoli Pharma (FY Dec-2025) | Haitian Ruisheng (FY Dec-2025) |
|---|---|---|---|---|
Revenue | KRW 57.6 bn | RMB 6,265.5 m | RMB 3,041 m | RMB 377.0 m |
Revenue growth YoY | -18.2% | -8.4% | +18.0% | +59.0% |
Net income | KRW 12.7 bn | RMB 782.2 m | RMB 632 m | RMB 14.1 m |
Net margin | 22.1% | 12.5% | 20.8% | 3.7% |
Gross margin | ~30.0% (derived) | 67.4% (FY2024 main business) | 63.0% (H1 2025) | 48% |
Recent Developments
Only 23 dated entries could be verified for the 18-month window.



